Use of a decision support tool seemed to improve risk-appropriate, guideline-adherent colony-stimulating factor (CSF) use in lung cancer patients, according to a retrospective cohort study involving nearly 3,500 individuals.

Participants—all of whom had lung cancer—were treated at oncology practices in 14 states. The states either did (n=1,150) or did not (n=974) implement the tool. Investigators evaluated both groups pre- and post-intervention, looking specifically at differences in CSF use and febrile neutropenia (FN) incidence. Among the results:

• There were no differences in FN risk factors at baseline.
• After adjusting for certain variables, CSF use decreased from 48% to 36% in intervention states; it rose from 43% to 44% in the nonintervention states.
• FN rates were consistent for both groups during both periods.